483
Regeneron Pharmaceuticals IncFDA 483 - Regeneron Pharmaceuticals Inc - March 22, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Record Details
An FDA inspection of Regeneron Pharmaceuticals Inc. in Rensselaer, NY, identified a significant deficiency in their quality system. The firm lacked written procedures for production and process controls, specifically concerning a Process Performance Qualification study for drug product formulation. This indicates a failure to ensure drug products consistently meet identity, strength, quality, and purity standards.
Open in Dashboard
ID · 42489734-29a2-46d5-96fb-7559354403d0